PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.13%
EBIT growth 50-75% of AGEN's 70.58%. Martin Whitman would suspect suboptimal resource allocation.
37.34%
Operating income growth at 50-75% of AGEN's 66.66%. Martin Whitman would doubt the firm’s ability to compete efficiently.
47.13%
Net income growth at 50-75% of AGEN's 67.53%. Martin Whitman would question fundamental disadvantages in expenses or demand.
50.90%
EPS growth at 50-75% of AGEN's 70.70%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
52.86%
Diluted EPS growth at 50-75% of AGEN's 70.70%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
7.67%
Share count expansion well above AGEN's 10.73%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
12.32%
Diluted share count expanding well above AGEN's 10.73%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
33.57%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
33.08%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9761.92%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-7404.36%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-3986.05%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-11268.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-11424.82%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
97.34%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
7616.79%
5Y equity/share CAGR above 1.5x AGEN's 1298.58%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
547.30%
Below 50% of AGEN's 3493.90%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Negative asset growth while AGEN invests at 34.70%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.66%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
We’re deleveraging while AGEN stands at 868.72%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-26.31%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-49.44%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.